🇺🇸 FDA
Patent

US 11976293

Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies

granted A61KA61K35/28A61K48/005

Quick answer

US patent 11976293 (Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies) held by The Regents of the University of California expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K35/28, A61K48/005, A61P, A61P7/00